

# FREQUENTLY ASKED QUESTIONS

**LOVAZA**<sup>®</sup>  
omega-3-acid ethyl esters

## SEVERE HYPERTRIGLYCERIDEMIA AND LOVAZA

VOLUME 04 • SEPTEMBER 2010

### MATTHEW ITO, PHARM.D, CLS, FCCP, FNLA

Professor of Pharmacy Practice

Oregon State University

Oregon Health & Science University

Portland, Oregon

### MARK CZIRAKY, PHARM.D, CLS, FAHA, FNLA

Vice President, Research Development & Operations

HealthCore Inc.

Wilmington, Delaware

Adjunct Assistant Professor

Philadelphia College of Pharmacy

University of the Sciences in Philadelphia


Philadelphia, Pennsylvania

## Q&A

#### Q1. What are omega-3 fatty acids and where do they come from?

A1.  $\alpha$ -Linolenic acid (ALA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA) are the most common omega-3 fatty acids (Figure 1).<sup>1</sup> ALA is widely consumed in nuts and legumes and some vegetable oils,<sup>1</sup> but has not shown consistent or robust effects on triglycerides (TGs), and is poorly converted to EPA,<sup>2</sup> DHA and EPA, on the other hand, have been shown consistently to lower TGs in multiple clinical trials.<sup>3</sup> DHA is a 22-carbon chain, with 6 double bonds that start 3 carbons from the terminal end (22:6n-3). Likewise, EPA is a 20-carbon chain with 5 double bonds that begin 3 carbons from the terminal end (22:6n-3).

Figure 1. Chemical Structures of Omega-3 Fatty Acids<sup>4</sup>



DHA and EPA are enriched in marine mammals and "fatty" fish like tuna, salmon, sardines, herring, and mackerel.<sup>4</sup> Based on the NHANES survey (1999-2000), the typical American consumes about 100 mg of DHA and EPA per day in the diet.<sup>5</sup> The average DHA and EPA content of various types of fish is listed in Table 1.<sup>4</sup> Some omega-3 fatty acid dietary supplements (capsules or oils) can provide DHA and/or EPA as well. LOVAZA, a highly concentrated and purified formulation, is the only prescription DHA and EPA indicated for treatment of severe hypertriglyceridemia (TGs  $\geq 500$  mg/dL).<sup>6</sup>

Table 1. Approximate levels of EPA and DHA in dry-heat cooked fish\*

Fish	EPA and DHA (g/4 oz eaten)
Salmon, Atlantic farmed	2.44
Herring, Pacific	2.41
Mackerel, Pacific and jack	2.10
Salmon, Atlantic wild	2.08
Salmon, Chinook	1.97
Whitefish	1.82
Tuna, bluefin	1.70
Salmon, Coho farmed	1.45
Mackerel, Atlantic	1.36
Halibut, Greenland	1.34
Trout, rainbow farmed	1.30
Salmon, Coho wild	1.20
Halibut, Atlantic and Pacific	0.53
Tuna, yellowfin	0.32
Cod, Pacific	0.32


\*Cooked fish (dry heat) often has less omega-3 fatty acid content than raw fish. The amount of omega-3 fatty acids varies considerably in the same type of fish, depending on environment and location.

Adapted from Bays et al.<sup>4</sup>

#### Q2. What is LOVAZA?

A2. LOVAZA (GlaxoSmithKline, Research Triangle Park, North Carolina) is the only prescription omega-3-acid ethyl esters indicated as an adjunct to diet to lower TGs in adult patients with severe hypertriglyceridemia (TGs  $\geq 500$  mg/dL).<sup>6</sup> Each 1-g capsule of LOVAZA contains at least 900 mg of omega-3 fatty acid ethyl esters, of which DHA makes up ~375 mg and EPA ~465 mg.<sup>6</sup> The omega-3 fatty acids in LOVAZA are derived from fish.<sup>6</sup>

Figure 2. Effects of LOVAZA 4 g/day on lipid parameters in patients with severe hypertriglyceridemia<sup>6</sup>



**Q3. What is the proven effectiveness of LOVAZA for lowering TGs in adult patients with severe hypertriglyceridemia (TGs ≥500 mg/dL)?**

**A3.** LOVAZA 4 g per day was evaluated as monotherapy in 2 randomized, placebo-controlled, double-blind, parallel-group studies.<sup>6-8</sup> Adult patients with TG levels between 500 and 2,000 mg/dL were included in the studies. After 4-6 weeks of dietary run-in, half of the patients were randomized to receive LOVAZA and half to placebo for 6 or 16 weeks.<sup>6-8</sup> Among all participants, the median baseline TG, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels were 816 mg/dL, 89 mg/dL, and 22 mg/dL, respectively.<sup>6</sup> Composite results from the 2 studies are presented in Figure 2. TG levels decreased by 45% in patients who received LOVAZA. LDL-C increased by 45% from a median baseline of 89 mg/dL to 109 mg/dL. When lowering a patient's very high triglyceride level, normal lipid metabolism may be restored. The increased conversion of very low-density lipoprotein (VLDL) to LDL may result in an increase in LDL-C. Additionally, patients receiving LOVAZA experienced a 9% increase in HDL-C, and decreases in non-HDL-C (-14%), VLDL-C (-42%), and total cholesterol (-10%).

**Q4. What should patients be aware of before taking LOVAZA?**

**A4.** LOVAZA comes as 1-g liquid-filled capsules, and may be taken as a single 4-g dose or two 2-g doses to equal the daily dose of 4 g per day.<sup>6</sup> LOVAZA should be used with caution in patients with known sensitivity

or allergy to fish.<sup>6</sup> LOVAZA is contraindicated in patients who exhibit hypersensitivity to any component of the medication.<sup>6</sup> TG and LDL-C levels should be monitored periodically during therapy with LOVAZA.<sup>6</sup> Alanine aminotransferase and aspartate aminotransferase levels should be monitored in patients with known hepatic dysfunction.<sup>6</sup> Also, patients receiving treatment with both LOVAZA and an anticoagulant or other drug affecting coagulation should be monitored periodically.<sup>6</sup>

LOVAZA has a demonstrated safety and tolerability profile.<sup>7,8</sup> In clinical trials with LOVAZA, the most common adverse events reported were eructation, infection, flu syndrome, dyspepsia, and taste perversion.<sup>6</sup> In 8 randomized, placebo-controlled, double-blind, parallel-group studies for hypertriglyceridemia, 3.5% of patients treated with LOVAZA and 2.6% of patients treated with placebo discontinued the study because of treatment-emergent adverse events.<sup>6</sup>

**Q5. What are the differences between LOVAZA and dietary supplements?**

**A5.** Patients may incorrectly assume that prescription drugs and dietary supplements are manufactured and produced according to the same set of FDA regulations.<sup>9</sup> However, different regulations apply to manufacturing and production of prescription omega-3 fatty acid ethyl esters (P-OM3) and omega-3 dietary supplements (Table 2).<sup>10</sup> The FDA has established Current Good Manufacturing Practices (cGMPs) for manufacturers of dietary supplements and prescription drugs to follow.<sup>11-13</sup> Manufacturers' compliance with cGMPs helps

Table 2. Regulatory Differences Between Dietary Supplements and P-OM3<sup>10</sup>

	P-OM3	Omega-3 Dietary Supplement
Efficacy, as demonstrated in clinical trials is mandatory	YES	NO
Documentation of safety and tolerability is mandatory	YES	NO
Contents of capsule regulated by FDA (mandatory compliance with processing of API)	YES	NO
Mandatory compliance with the Federal Food, Drug and Cosmetic Act	YES	NO
FDA-approved for the treatment of severe hypertriglyceridemia in adults	YES	NO

API = Active pharmaceutical ingredients.

ensure batch-to-batch consistency. However, the FDA inspects pharmaceutical manufacturing facilities prior to product approval to ensure manufacturing occurs according to cGMPs.<sup>13</sup>

Additionally, the FDA approves prescription drugs before they are made available to consumers.<sup>13</sup> After a new drug is evaluated in laboratory and animal studies, the safety and efficacy of the drug is then determined in human clinical trials.<sup>14</sup> A team of physicians, statisticians, chemists, and pharmacologists at the FDA's Center for Drug Evaluation and Research then reviews the data and proposed drug labeling.<sup>14</sup> Provided the benefits and evidence of efficacy outweigh the risks of the drug, the drug is approved and made available via prescription.<sup>14</sup> LOVAZA® (omega-3-acid ethyl esters) is the only FDA-approved prescription source of omega-3 fatty acids for the treatment of severe hypertriglyceridemia (TGs  $\geq 500$  mg/dL), and each capsule is manufactured according to strict standards.

#### Q6. What are TGs and where do they come from?

**A6.** TGs are fats composed of three fatty acids joined to a glycerol molecule.<sup>15</sup> They are obtained from foods that contain fats, or are made in the liver and intestine from free fatty acids.<sup>16</sup> TGs provide energy to muscles and other cells. Those in excess of energy needs are stored in adipose tissue, or in some cases (such as severe hypertriglyceridemia), they can be stored in other tissues such as muscle and the liver.<sup>17</sup>

#### Q7. How do TGs become very high?

**A7.** The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) issued guidelines for assessing fasting plasma TG levels, ranging from "normal" to "very high" (Table 3).<sup>18</sup> When TGs are very high ( $\geq 500$  mg/dL; severe hypertriglyceridemia), NCEP recommends that lowering TGs be the primary goal of therapy.<sup>18</sup> There are a number of factors that can result in increased TG levels, and in many cases, severe hypertriglyceridemia results from the presence of multiple factors.<sup>18</sup> Some of those risk factors that can converge to cause severe hypertriglyceridemia include heredity, medications, medical conditions, and lifestyle choices.<sup>18</sup> Genetic influences play a role—some people with severe hypertriglyceridemia have a family or personal history of lipid abnormalities.<sup>18</sup> A number of medications can cause increases in TGs (Table 4).<sup>19</sup> Certain illnesses are also associated with a rise in TGs, including untreated hypothyroidism, chronic renal failure, nephrotic syndrome, non-alcoholic fatty liver disease, type 2 diabetes,<sup>20</sup> and polycystic ovarian syndrome.<sup>21</sup>

An especially important influence on TG levels is lifestyle.<sup>18</sup> A high-calorie diet, or a diet high in fats or carbohydrates and low in fiber, can increase TGs, as can lack of exercise, or a generally sedentary lifestyle. Excessive alcohol consumption is also known to raise TG levels.<sup>20</sup>

Table 3. NCEP ATP III Classification of Hypertriglyceridemia<sup>18</sup>

ATP III Category	Plasma TGs (mg/dL)
Normal	<150
Moderately High	150 - 199
High	200 - 499
Very High*	$\geq 500$

\*Referred to here as severe hypertriglyceridemia.

#### Q8. Can patients lower TGs without taking medication?

**A8.** Because genetic factors cannot be altered, the first step is to look for secondary factors that can be addressed.<sup>18</sup> If a patient is taking a medication that might increase TG levels (Table 4), he or she should discuss alternative treatments with his or her practitioner. If a patient has a medical condition that is known to influence TG levels, he or she should discuss management options with the health practitioner. Changing daily habits to reflect a healthier lifestyle can be very effective for lowering TGs—this can mean eating fewer calories overall, keeping fat consumption down to 25-35% or less of daily caloric intake, eating foods high in fiber such as vegetables, fruits, and whole grains, and exercising regularly.<sup>18</sup> Achieving and maintaining a healthy weight can benefit patients with severe hypertriglyceridemia who are overweight.<sup>18</sup> Additionally, the American Heart Association advises patients with TG elevation to increase intake of certain omega-3 polyunsaturated fatty acids.<sup>22</sup>

Table 4. Medications that May Increase TG Levels<sup>19</sup>

<b>Cardiovascular drugs</b>
Diuretics – thiazide, loop
$\beta$ -blockers
<b>Hormones, hormone-related</b>
Unopposed estrogen
Combined oral contraceptive with 2nd generation progestogen
Combined oral contraceptive with 3rd generation progestogen
Tamoxifen
<b>Synthetic Retinoids</b>
Isotretinoin
Acitretin
<b>Protease inhibitors</b>
Ritonavir, indinavir/nelfinavir
<b>Antipsychotics</b>
Clozapine, other

#### Q9. How does LOVAZA reduce TG levels in patients with severe hypertriglyceridemia?

**A9.** The mechanism of action of LOVAZA is not fully understood, yet a few mechanisms have been proposed. Proposed mechanisms of action for DHA and EPA include inhibition of acyl CoA:1,2-diaclyglycerol acyltransferase (an enzyme involved in lipogenesis), increases in mitochondrial and peroxisomal  $\beta$ -oxidation in the liver (increasing fatty acid degradation), decreases in VLDL assembly in the liver, and increases in plasma lipoprotein lipase activity (removing TGs from circulating lipoproteins).<sup>6,23-25</sup> LOVAZA is also thought to lower TGs by reducing lipogenesis in the liver, because EPA and DHA are poor substrates for the enzymes responsible for TG synthesis.<sup>6,23</sup>

#### Q10. LOVAZA is derived from fish oils. Are there any contaminants in LOVAZA?

**A10.** The fish oils in LOVAZA are purified by a 5-step process that helps to remove environmental toxins, short-chain fatty acids, oxidized fatty acids, cholesterol and proteins, and saturated fatty acids.<sup>4</sup> Additionally, purification of LOVAZA yields less than 90 mg of omega-6, -7, and -9 fatty acids, less than 0.1% of trans fatty acids, and minimizes the content of heavy metals, halogenated polycarbons, and dioxins.<sup>26</sup>

## INDICATION

LOVAZA® (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe ( $\geq 500$  mg/dL) hypertriglyceridemia.

## IMPORTANT SAFETY INFORMATION

LOVAZA is contraindicated in patients who exhibit hypersensitivity to any component of this medication.

In patients with hepatic impairment, ALT and AST levels should be monitored periodically. In some patients, LOVAZA increases LDL-C and ALT levels (without a concurrent increase in AST). TG and LDL-C levels should be monitored periodically during therapy with LOVAZA.

LOVAZA should be used with caution in patients with known hypersensitivity or allergy to fish and/or shellfish.

Some studies with omega-3-acids demonstrated prolongation of bleeding time, which did not exceed normal limits and did not produce clinically significant bleeding episodes. Clinical studies have not been done to thoroughly examine the effect of LOVAZA and concomitant anticoagulants. Patients receiving treatment with both LOVAZA and anticoagulants should be monitored periodically.

The most common adverse events reported were eructation, infection, flu syndrome, dyspepsia, and taste perversion. Discontinuation of treatment due to adverse events was similar to placebo: 3.5% of patients treated with LOVAZA and 2.6% of patients treated with placebo.

The effect of LOVAZA on cardiovascular mortality and morbidity in patients with elevated TG levels has not been determined.

**How supplied:** 1-gram capsules.

Please see the accompanying complete Prescribing Information for LOVAZA.

## Acknowledgments

This newsletter was sponsored by GlaxoSmithKline, Research Triangle Park, North Carolina. Drs. Ito and Cziraky were compensated for their participation, were fully involved in the newsletter development, and assume responsibility for the content. At his request, Dr. Cziraky's compensation was donated to the charity of his choice. Editorial support was provided by Amanda McGeary, MS, and Melanie Watson, PhD, at AlphaBioCom, LLC, with funding from GlaxoSmithKline.

## References

1. Kris-Etherton PM, Taylor DS, Yu-Poth S, et al. Polyunsaturated fatty acids in the food chain in the United States. *Am J Clin Nutr*. 2000;71:179S-88S.
2. Balk EM, Lichtenstein AH, Chung M, et al. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. *Atherosclerosis*. 2006;189:19-30.
3. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. *Am J Clin Nutr*. 1997;65:1645S-54S.
4. Bays H. Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians. *Drugs Today (Barc)*. 2008;44:205-48.
5. Ervin RB, Wright JD, Wang CY, Kennedy-Stephenson J. Dietary intake of fats and fatty acids for the United States population: 1999-2000. *Adv Data*. 2004;1-6.
6. Prescribing Information for LOVAZA, GlaxoSmithKline.
7. Harris WS, Ginsberg HN, Anurakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. *J Cardiovasc Risk*. 1997;4:385-91.
8. Pownall HJ, Brauchi D, Kline C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. *Atherosclerosis*. 1999;143:265-97.
9. Hoffman VA. Regulation of dietary supplements in the United States: understanding the dietary supplement health and education act. *Clin Obstet Gynecol*. 2001;44:780-8.
10. Collins N, Tighe AP, Brunton SA, Kris-Etherton PM. Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective. *J Am Coll Nutr*. 2008;27:659-66.
11. Bays HE. Safety considerations with omega-3 fatty acid therapy. *Am J Cardiol*. 2007;99:35C-43C.
12. Food and Drug Administration. Overview of Dietary Supplements. 2009. Available at: <http://www.fda.gov/Food/DietarySupplements/ConsumerInformation/ucm110417.htm#regulate>. Accessed June 30, 2009.
13. Food and Drug Administration. Facts About Current Good Manufacturing Practices (cGMPs). 2009. Available at: <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm169105.htm>. Accessed July 30, 2009.
14. Food and Drug Administration. Approved Drugs: Questions and Answers. 2009. Available at: <http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm>. Accessed August 12, 2009.
15. Ginsberg HN. Lipoprotein metabolism and its relationship to atherosclerosis. *Med Clin North Am*. 1994;78:1-20.
16. Lewis GF. Fatty acid regulation of very low density lipoprotein production. *Curr Opin Lipidol*. 1997;8:146-53.
17. Schraffer JE. Lipotoxicity: when tissues overeat. *Curr Opin Lipidol*. 2003;14:281-287.
18. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106:3143-421.
19. Martel-Tesewisse AK, Kloosterman JM, Maltand-van der Zee AH, et al. Drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. *Drug Saf*. 2001;24:443-56.
20. Yuan G, Al-Shall KZ, Heggie RA. Hypertriglyceridemia: its etiology, effects and treatment. *CMAJ*. 2007;176:1113-20.
21. Bornes K, Rizzo M, Hensberger M, et al. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome. *Int J Clin Pract*. 2009;63:56-62.
22. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. *Circulation*. 2002;106:2747-57.
23. Bays HE, Tighe AP, Sadovskiy R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. *Expert Rev Cardiovasc Ther*. 2008;6:391-409.
24. Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. *Am J Cardiol*. 2006;98:275-33.
25. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? *Curr Opin Lipidol*. 2006;17:387-93.
26. Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. *Am J Cardiol*. 2006;98:711-6.



LOVAZA is a registered trademark of GlaxoSmithKline.

All other products are registered trademarks of their respective companies.




# LOVAZA®

(omega-3-acid ethyl esters)  
Capsules


**DESCRIPTION**

LOVAZA, a lipid-regulating agent, is supplied as a liquid-filled gel capsule for oral administration. Each 1-gram capsule of LOVAZA (omega-3-acid ethyl esters) contains at least 900 mg of the ethyl esters of omega-3 fatty acids. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg).

The structural formula of EPA ethyl ester is:



The empirical formula of EPA ethyl ester is C<sub>32</sub>H<sub>54</sub>O<sub>2</sub>, and the molecular weight of EPA ethyl ester is 330.51. The structural formula of DHA ethyl ester is:



The empirical formula of DHA ethyl ester is C<sub>34</sub>H<sub>58</sub>O<sub>2</sub>, and the molecular weight of DHA ethyl ester is 356.55.

LOVAZA capsules also contain the following inactive ingredients: 4 mg α-tocopherol (in a carrier of partially hydrogenated vegetable oils including soybean oil), and gelatin, glycerol, and purified water (components of the capsule shell).

**CLINICAL PHARMACOLOGY**

**Mechanism of Action:** The mechanism of action of LOVAZA is not completely understood. Potential mechanisms of action include inhibition of acyl CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal β-oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity. LOVAZA may reduce the synthesis of triglycerides (TGs) in the liver because EPA and DHA are poor substrates for the enzymes responsible for TG synthesis, and EPA and DHA inhibit esterification of other fatty acids.

**Pharmacokinetic and Bioavailability Studies:** In healthy volunteers and in patients with hypertriglyceridemia (HTG), EPA and DHA were absorbed when administered as ethyl esters orally. Omega-3-acids administered as ethyl esters (LOVAZA) induced significant, dose-dependent increases in serum phospholipid EPA content, though increases in DHA content were less marked and not dose-dependent when administered as ethyl esters. Uptake of EPA and DHA into serum phospholipids in subjects treated with LOVAZA was independent of age (<49 years versus >49 years). Females tended to have more uptake of EPA into serum phospholipids than males. Pharmacokinetic data on LOVAZA in children are not available.

**Drug Interactions: Cytochrome P450-Dependent Monooxygenase Activities:** The effect of a mixture of free fatty acids (FFA), EPA/DHA and their FFA-albumin conjugate on cytochrome P450-dependent monooxygenase activities was assessed in human liver microsomes. At the 23 micromole concentration, FFA resulted in a less than 32% inhibition of CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A. At the 23 micromole concentration, the FFA-albumin conjugate resulted in a less than 20% inhibition of CYP2A6, 2C19, 2D6, and 3A, with a 68% inhibition being seen for CYP2E1. Since the free forms of the EPA and DHA are undetectable in the circulation (<1 micromole), clinically significant drug-drug interactions due to inhibition of P450-mediated metabolism EPA/DHA combinations are not expected in humans.

**CLINICAL STUDIES**

**High Triglycerides: Add-on to HMG-CoA reductase inhibitor therapy:** The effects of LOVAZA 4 g per day as add-on therapy to treatment with simvastatin were evaluated in a randomized, placebo-controlled, double-blind, parallel-group study of 254 adult patients (122 on LOVAZA and 132 on placebo) with persistent high triglycerides (200 to 499 mg/dL) despite simvastatin therapy (Table 1). Patients were treated with open-label simvastatin 40 mg per day for 8 weeks prior to randomization to control their LDL-C to no greater than 10% above NCEP ATP II goal and remained on this dose throughout the study. Following the 8 weeks of open-label treatment with simvastatin, patients were randomized to either LOVAZA 4 g per day or placebo for an additional 8 weeks with simvastatin co-therapy. The median baseline triglyceride and LDL-C levels in these patients were 288 mg/dL and 89 mg/dL, respectively. Median baseline non-HDL-C and HDL-C levels were 138 mg/dL and 45 mg/dL, respectively.

The changes in the major lipoprotein lipid parameters for the groups receiving LOVAZA plus simvastatin and the placebo plus simvastatin groups are shown in Table 1.

**Table 1. Response to the Addition of LOVAZA 4 g per day to On-going Simvastatin 40 mg per day Therapy in Patients With High Triglycerides (200 to 499 mg/dL)**

Parameter	LOVAZA + Simvastatin N = 122			Placebo + Simvastatin N = 132			Difference	P-Value
	BL	EOT	Median % Change	BL	EOT	Median % Change		
Non-HDL-C	137	123	-9.0	141	134	-2.2	-6.8	<0.0001
TG	268	182	-29.5	271	260	-6.3	-23.2	<0.0001
TC	184	172	-4.8	184	178	-1.7	-3.1	<0.05
VLDL-C	52	37	-27.5	52	49	-7.2	-20.3	<0.05
Apo-B	85	80	-4.2	87	85	-1.9	-2.3	<0.05
HDL-C	46	48	+3.4	43	44	-1.2	+4.6	<0.05
LDL-C	91	88	+0.7	88	85	-2.8	+3.5	=0.05

BL = Baseline (mg/dL), EOT = End of Treatment (mg/dL), Median % Change = Median Percent Change from Baseline, Difference = LOVAZA Median % Change - Placebo Median % Change

LOVAZA 4 g per day significantly reduced non-HDL-C, TG, TC, VLDL-C, and Apo-B levels, and increased HDL-C and LDL-C from baseline relative to placebo.

**Very High Triglycerides: Monotherapy:** The effects of LOVAZA 4 g per day were assessed in two randomized, placebo-controlled, double-blind, parallel-group studies of 84 adult patients (42 on LOVAZA, 42 on placebo) with very high triglyceride levels (Table 2). Patients whose baseline triglyceride levels were between 500 and 2,000 mg/dL were enrolled in these 2 studies of 6 and 16 weeks' duration. The median triglyceride and LDL-C levels in these patients were 792 mg/dL and 100 mg/dL, respectively. Median HDL-C level was 23.0 mg/dL.

The changes in the major lipoprotein lipid parameters for the groups receiving LOVAZA or placebo are shown in Table 2.

**Table 2. Median Baseline and Percent Change From Baseline in Lipid Parameters in Patients With Very High TG Levels (≥500 mg/dL)**

Parameter	LOVAZA N = 42		Placebo N = 42		Difference
	BL	% Change	BL	% Change	
TG	816	-44.9	788	+6.7	-51.6
Non-HDL-C	271	-13.8	292	-3.6	-10.2
TC	296	-9.7	314	-1.7	-8.0
VLDL-C	175	-41.7	175	-0.9	-40.8
HDL-C	22	+9.1	24	0.0	+9.1
LDL-C	89	+44.5	108	-4.8	+49.3

BL = Baseline (mg/dL), % Chg = Median Percent Change from Baseline; Difference = LOVAZA Median % change - Placebo Median % Change

LOVAZA 4 g per day reduced median TG, VLDL-C, and non-HDL-C levels and increased median HDL-C from baseline relative to placebo. Treatment with LOVAZA to reduce very high TG levels may result in elevations in LDL-C and non-HDL-C in some individuals. Patients should be monitored to ensure that the LDL-C level does not increase excessively.

The effect of LOVAZA on the risk of pancreatitis in patients with very high TG levels has not been evaluated.

The effect of LOVAZA on cardiovascular mortality and morbidity in patients with elevated TG levels has not been determined.

**INDICATIONS AND USAGE**

**Very High Triglycerides:** LOVAZA is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with very high (≥500 mg/dL) triglyceride levels.

**Usage Considerations:** In individuals with hypertriglyceridemia (HTG), excess body weight and excess alcohol intake may be important contributing factors and should be addressed before initiating any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, (such as hypothyroidism or diabetes mellitus) should be looked for and adequately treated. Estrogen therapy, thiazide diuretics, and beta blockers are sometimes associated with massive rises in plasma TG levels. In such cases, discontinuation of the specific etiologic agent, if medically indicated, may obviate the need for specific drug therapy for HTG.

The use of lipid-regulating agents should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use lipid-regulating agents, the patient should be advised that use of lipid-regulating agents does not reduce the importance of adhering to diet (see PRECAUTIONS).

**CONTRAINDICATIONS**

LOVAZA is contraindicated in patients who exhibit hypersensitivity (e.g., anaphylactic reaction) to any component of this medication.

**PRECAUTIONS**

**General: Initial Therapy:** Laboratory studies should be performed to ascertain that the patient's TG levels are consistently abnormal before instituting therapy with LOVAZA. Every attempt should be made to control serum TG levels with appropriate diet, exercise, weight loss in overweight patients, and control of any medical problems (such as diabetes mellitus and hypothyroidism) that may be contributing to the patient's TG abnormalities. Medications known to exacerbate HTG (such as beta blockers, thiazides, and estrogens) should be discontinued or changed, if possible, before considering TG-lowering drug therapy.

**Continued Therapy:** Laboratory studies should be performed periodically to measure the patient's TG levels during therapy with LOVAZA. Therapy with LOVAZA should be withdrawn in patients who do not have an adequate response after 2 months of treatment.

**Information for Patients:** LOVAZA should be used with caution in patients with known sensitivity or allergy to fish.

Patients should be advised that use of lipid-regulating agents does not reduce the importance of adhering to diet.

**Laboratory Tests:** In some patients, increases in alanine aminotransferase (ALT) levels without a concurrent increase in aspartate aminotransferase (AST) levels were observed. Alanine aminotransferase levels should be monitored periodically during therapy with LOVAZA.

In some patients, LOVAZA increased low-density lipoprotein cholesterol (LDL-C) levels. As with any lipid-regulating product, LDL-C levels should be monitored periodically during therapy with LOVAZA.

**Drug Interactions: Anticoagulants:** Some studies with omega-3-acid ethyl esters demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in these studies has not exceeded normal limits and did not produce clinically significant bleeding episodes. Clinical studies have not been done to thoroughly examine the effect of LOVAZA and concomitant anticoagulants. Patients receiving treatment with both LOVAZA and anticoagulants should be monitored periodically.

**HMG-CoA reductase inhibitors:** In a 14-day study of 24 healthy adult subjects, daily co-administration of simvastatin 80 mg with LOVAZA 4 g did not affect the extent (AUC) or rate (C<sub>max</sub>) of exposure to simvastatin or the major active metabolite, beta-hydroxy simvastatin at steady state.

**Cytochrome P450-Dependent Monooxygenase Activities:** Omega-3 fatty-acid-containing products have been shown to increase hepatic concentrations of cytochrome P450 and activities of certain P450 enzymes in rats. The potential of LOVAZA to induce P450 activities in humans has not been studied.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** In a rat carcinogenicity study with oral gavage doses of 100, 600, and 2,000 mg/kg/day, males were treated with omega-3-acid ethyl esters for 101 weeks and females for 89 weeks without an increased incidence of tumors (up to 5 times human systemic exposures following an oral dose of 4 g/day based on a body surface area comparison). Standard lifetime carcinogenicity bioassays were not conducted in mice.

Omega-3-acid ethyl esters were not mutagenic or clastogenic with or without metabolic activation in the bacterial mutagenesis (Ames) test with *Salmonella typhimurium* and *Escherichia coli* or in the chromosomal aberration assay in Chinese hamster V79 lung cells or human lymphocytes. Omega-3-acid ethyl esters were negative in the *in vivo* mouse micronucleus assay.

In a rat fertility study with oral gavage doses of 100, 600, and 2,000 mg/kg/day, males were treated for 10 weeks prior to mating and females were treated for 2 weeks prior to and throughout mating, gestation, and lactation. No adverse effect on fertility was observed at 2,000 mg/kg/day (5 times human systemic exposure following an oral dose of 4 g/day based on a body surface area comparison).

**Pregnancy Category C:** There are no adequate and well-controlled studies in pregnant women. It is unknown whether LOVAZA can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. LOVAZA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Omega-3-acid ethyl esters have been shown to have an embryocidal effect in pregnant rats when given in doses resulting in exposures 7 times the recommended human dose of 4 g/day based on a body surface area comparison.

In female rats given oral gavage doses of 100, 600, and 2,000 mg/kg/day beginning two weeks prior to mating and continuing through gestation and lactation, no adverse effects were observed in the high dose group (5 times human systemic exposure following an oral dose of 4 g/day based on body surface area comparison).

In pregnant rats given oral gavage doses of 1,000, 3,000, and 6,000 mg/kg/day from gestation day 6 through 15, no adverse effects were observed (14 times human systemic exposure following an oral dose of 4 g/day based on a body surface area comparison).

In pregnant rats given oral gavage doses of 100, 600, and 2,000 mg/kg/day from gestation day 14 through lactation day 21, no adverse effects were seen at 2,000 mg/kg/day (5 times the human systemic exposure following an oral dose of 4 g/day based on a body surface area comparison). However, decreased live births (20% reduction) and decreased survival to postnatal day 4 (40% reduction) were observed in a dose-ranging study using higher doses of 3,000 mg/kg/day (7 times the human systemic exposure following an oral dose of 4 g/day based on a body surface area comparison).

In pregnant rabbits given oral gavage doses of 375, 750, and 1,500 mg/kg/day from gestation day 7 through 19, no findings were observed in the fetuses in groups given 375 mg/kg/day (2 times human systemic exposure following an oral dose of 4 g/day based on a body surface area comparison). However, at higher doses, evidence of maternal toxicity was observed (4 times human systemic exposure following an oral dose of 4 g/day based on a body surface area comparison).

**Nursing Mothers:** It is not known whether omega-3-acid ethyl esters are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when LOVAZA is administered to a woman who is breastfeeding.

**Pediatric Use:** Safety and effectiveness in pediatric patients under 18 years of age have not been established.

**Geriatric Use:** A limited number of patients older than 65 years were enrolled in the clinical studies. Safety and efficacy findings in subjects older than 60 years did not appear to differ from those of subjects younger than 60 years.

## ADVERSE REACTIONS

Treatment-emergent adverse events reported in at least 1% of patients treated with LOVAZA 4 g per day or placebo during 8 randomized, placebo-controlled, double-blind, parallel-group studies for HTG are listed in Table 3. Adverse events led to discontinuation of treatment in 3.5% of patients treated with LOVAZA and 2.6% of patients treated with placebo.

**Table 3. Adverse Events in Randomized, Placebo-Controlled, Double-Blind, Parallel Group Studies for Very High TG Levels (≥500 mg/dL) That Used LOVAZA 4 g per Day**

BODY SYSTEM Adverse Event	LOVAZA (N = 228)		Placebo* (N = 228)	
	n	%	n	%
Subjects with all least 1 adverse event	80	35.4	63	27.6
Body as a whole				
Back pain	5	2.2	3	1.3
Flu syndrome	8	3.5	3	1.3
Infection	10	4.4	5	2.2
Pain	4	1.8	3	1.3
Cardiovascular				
Angina pectoris	3	1.3	2	0.9
Digestive				
Dyspepsia	7	3.1	6	2.6
Eructation	11	4.9	5	2.2
Skin				
Rash	4	1.8	1	0.4
Special senses				
Taste perversion	6	2.7	0	0.0

Adverse events were coded using COSTART, version 5.0. Subjects were counted only once for each body system and for each preferred term.

\*Placebo was corn oil for all studies.

Additional adverse events reported by 1 or more patients from 22 clinical studies for HTG are listed below.

**Body as a Whole:** Enlarged abdomen, asthenia, body odor, chest pain, chills, suicide, fever, generalized edema, fungal infection, malaise, neck pain, neoplasm, rheumatoid arthritis, and sudden death.

**Cardiovascular System:** Arrhythmia, bypass surgery, cardiac arrest, hyperlipemia, hypertension, migraine, myocardial infarct, myocardial ischemia, occlusion, peripheral vascular disorder, syncope, and tachycardia.

**Digestive System:** Anorexia, constipation, dry mouth, dysphagia, colitis, fecal incontinence, gastritis, gastroenteritis, gastrointestinal disorder, increased appetite, intestinal obstruction, melena, pancreatitis, tenesmus, and vomiting.

**Hematologic-Lymphatic System:** Lymphadenopathy.

**Infections and Infestations:** Viral infection.

**Metabolic and Nutritional Disorders:** Edema, hyperglycemia, increased ALT, and increased AST.

**Musculoskeletal System:** Arthralgia, arthritis, myalgia, pathological fracture, and tendon disorder.

**Nervous System:** Central nervous system neoplasm, depression, dizziness, emotional lability, facial paralysis, insomnia, vasodilatation, and vertigo.

**Respiratory System:** Asthma, bronchitis, increased cough, dyspnea, epistaxis, laryngitis, pharyngitis, pneumonia, rhinitis, and sinusitis.

**Skin:** Alopecia, eczema, pruritus, and sweating.

**Special Senses:** Cataract.

**Urogenital System:** Cervix disorder, endometrial carcinoma, epididymitis, and impotence.

**Postmarketing Experience:** In addition to adverse reactions reported from clinical trials, the events described below have been identified during post-approval use of LOVAZA. Because these events are reported voluntarily from a population of unknown size, it is not possible to reliably estimate their frequency or to always establish a causal relationship to drug exposure.

The following events have been reported: anaphylactic reaction, hemorrhagic diathesis.

## DRUG ABUSE AND DEPENDENCE

LOVAZA does not have any known drug abuse or withdrawal effects.

## OVERDOSAGE

In the event of an overdose, the patient should be treated symptomatically, and general supportive care measures instituted, as required.

## DOSAGE AND ADMINISTRATION

Patients should be placed on an appropriate lipid-lowering diet before receiving LOVAZA, and should continue this diet during treatment with LOVAZA. In clinical studies, LOVAZA was administered with meals.

The daily dose of LOVAZA is 4 g per day. The daily dose may be taken as a single 4-g dose (4 capsules) or as two 2-g doses (2 capsules given twice daily).

## HOW SUPPLIED

LOVAZA (omega-3-acid ethyl esters) capsules are supplied as 1-gram transparent soft-gelatin capsules filled with light-yellow oil and bearing the designation REL900.

Bottles of 60. NDC 0173-0783-01

Bottles of 120. NDC 0173-0783-02

**Recommended Storage:** Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Do not freeze. Keep out of reach of children.

Distributed by:



GlaxoSmithKline  
Research Triangle Park, NC 27709

©2008 GlaxoSmithKline. All rights reserved.

November 2008

LVZ-3P1

## PATIENT INFORMATION

LOVAZA® (lō-vā-zā)  
(omega-3-acid ethyl esters) Capsules

Read the Patient Information that comes with LOVAZA before you start taking it, and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your condition or treatment.

## What is LOVAZA?

LOVAZA is a prescription medicine for adults called a lipid-regulating medicine. LOVAZA is made of omega-3 fatty acids. Omega-3 fatty acids are natural substances that your body needs. They are found naturally in some plants and in the oil of certain fish, such as salmon and mackerel.

LOVAZA is used along with a low-fat and low-cholesterol diet to lower very high triglycerides (fats) in your blood. Before taking LOVAZA, talk to your healthcare provider about how you can lower high blood fats by:

- losing weight, if you are overweight
- increasing physical exercise
- lowering alcohol use
- treating diseases such as diabetes and low thyroid (hypothyroidism)
- adjusting the dose or changing other medicines that raise triglyceride levels such as certain blood pressure medicines and estrogens

Treatment with LOVAZA has not been shown to prevent heart attacks or strokes.

LOVAZA has not been studied in children under the age of 18 years.

## Who should not take LOVAZA?

Do not take LOVAZA if you:

- are allergic to LOVAZA or any of its ingredients. See the end of this leaflet for a complete list of ingredients in LOVAZA.

## What should I tell my doctor before taking LOVAZA?

Tell your doctor about all of your medical conditions, including if you:

- drink more than 2 glasses of alcohol daily
- have diabetes
- have a thyroid problem called hypothyroidism
- have a liver problem
- have a pancreas problem
- are allergic to fish. LOVAZA may not be right for you.
- are pregnant, or planning to become pregnant. It is not known if LOVAZA can harm your unborn baby.
- are breastfeeding. It is not known if LOVAZA passes into your milk and if it can harm your baby.

Tell your doctor about all the medicines you take, including prescription and non-prescription medicine, vitamins and herbal supplements. LOVAZA and certain other medicines can interact causing serious side effects. Especially tell your doctor if you take medicines:

- to reduce clotting — known as anticoagulants or blood thinners. These include aspirin, warfarin, coumarin and clopidogrel (PLAVIX).

Know all the medicines you take. Keep a list of them with you to show your doctor and pharmacist.

## How should I take LOVAZA?

- Take LOVAZA exactly as prescribed. Do not change your dose or stop LOVAZA without talking to your doctor.

- The usual dose of LOVAZA is 4 capsules:
  - Take all 4 capsules at the same time, or
  - Take 2 capsules two times a day.

- Take LOVAZA at the same time or times each day.

- Take LOVAZA with or without food. You may find it easier to take LOVAZA with food.

- Do not take more than 4 capsules a day. Taking more than 4 capsules per day may increase the chance of side effects.

- Your doctor should start you on a low-fat and low-cholesterol diet before giving you LOVAZA. Stay on this low-fat and low-cholesterol diet while taking LOVAZA.

- Your doctor should do blood tests to check your triglyceride and cholesterol levels, and liver function during treatment with LOVAZA.

- If you miss a dose of LOVAZA, take it as soon as you remember. However, if you miss one day of LOVAZA, do not double your dose when you next take it.

- If you take too much LOVAZA or overdose, call your doctor or Poison Control Center right away.

## What are the possible side effects of LOVAZA?

- The most common side effects with LOVAZA are burping, infection, flu symptoms, upset stomach, a change in your sense of taste, back pain, and skin rash.

- LOVAZA may affect certain blood tests. It may change
  - one of the tests to check liver function (ALT)
  - one of the tests to measure cholesterol levels (LDL-C)

Talk to your doctor if you have side effects that bother you or that will not go away. You may report side effects to FDA at 1-800-FDA-1088.

These are not all the side effects with LOVAZA. Ask your doctor or pharmacist for a complete list.

## How should I store LOVAZA?

- Store LOVAZA at room temperature, 59° to 86° F (15° to 30° C). Do not freeze.
- Do not keep medicine that is out of date or that you no longer need.
- Keep LOVAZA out of the reach of children. Be sure that if you throw medicines away, it is out of the reach of children.

## General information about LOVAZA

Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use LOVAZA for a condition for which it was not prescribed. Do not give LOVAZA to other people, even if they have the same problem you have. It may harm them.

This leaflet summarizes the most important information about LOVAZA. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about LOVAZA that is written for health professionals or go to [www.LOVAZA.com](http://www.LOVAZA.com).

## What are the ingredients in LOVAZA?


Active Ingredient: Omega-3-acid ethyl esters

Inactive Ingredients: Gelatin, glycerol, purified water, alpha-tocopherol (in partially hydrogenated vegetable oils, including soybean oil)

LOVAZA is a registered trademark of the GlaxoSmithKline group of companies.

PLAVIX is a registered trademark of Sanofi-Synthelabo.

Distributed by:



GlaxoSmithKline  
Research Triangle Park, NC 27709

©2008 GlaxoSmithKline. All rights reserved.

June 2008

LVZ-1P1L